Jeong-Eun Kang

Title: Jeong-Eun Kang: Innovator in Monoclonal Antibody Research

Introduction

Jeong-Eun Kang is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of biomedical research, particularly in the development of human monoclonal antibodies. With a total of 3 patents to his name, Kang's work is paving the way for advancements in cancer treatment.

Latest Patents

One of Kang's latest patents is focused on a human monoclonal antibody that neutralizes vascular endothelial growth factor receptor. This invention relates to human ScFv molecules that inhibit angiogenesis and provide a composition for treating cancer. The disclosed monoclonal antibody demonstrates excellent neutralizing ability in living cells, outperforming commercially available antibodies against vascular endothelial growth factor receptor. It has shown effectiveness in neutralizing the receptor in humans, mice, and rats, making it a valuable asset in anticancer studies and treatment.

Career Highlights

Jeong-Eun Kang is currently associated with Pharmabcine Inc., where he continues to innovate in the field of antibody research. His work is characterized by a commitment to improving therapeutic options for cancer patients through advanced scientific methods.

Collaborations

Kang collaborates with notable colleagues, including Jin-San Yoo and Weon-Sup Lee. These partnerships enhance the research environment and contribute to the success of their projects.

Conclusion

Jeong-Eun Kang's contributions to monoclonal antibody research are noteworthy and have the potential to significantly impact cancer treatment. His innovative work at Pharmabcine Inc. and his collaborations with esteemed colleagues further solidify his position as a leading inventor in the field.